Quantcast

Latest Allergic conjunctivitis Stories

2010-02-12 07:00:00

Medication Delivered Under the Tongue May Be Alternative to Allergy Shots PITTSBURGH, Feb.

2009-11-27 03:49:00

PARIS, November 27 /PRNewswire-FirstCall/ -- Stallergenes has been granted European approval to market Oralair(R) in both adults and children through a Mutual Recognition Procedure.

2009-11-09 06:30:00

MIAMI, Nov. 9 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced additional results from the Company's Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies.

2009-10-21 15:01:00

ANAHEIM, Calif., Oct. 21 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) today announced poster presentations of results from the Company's Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies in allergic conjunctivitis.

2009-09-16 12:14:00

ANTONY, France, September 16 /PRNewswire-FirstCall/ -- Stallergenes S.A. has announced the first results of a new phase IIb/III clinical trial (VO59.08) conducted in allergic rhinitis caused by birch pollen and concerning the development of a sublingual immunotherapy tablet containing the recombinant allergen of this pollen, rBet v 1. This study is the first ever to use a recombinant allergen as an active substance.

2009-09-08 18:45:00

IRVINE, Calif., Sept. 8 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) today announced the U.S.

2009-06-26 09:28:00

IRVINE, Calif., June 26 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) today announced the Dermatologic and Ophthalmic Drugs Advisory Committee appointed by the U.S.

2009-06-01 12:13:00

IRVINE, Calif., June 1 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced it has received notification from the U.S.

2009-05-07 14:00:00

FT. LAUDERDALE, Fla., May 7 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc.

2009-05-04 02:00:00

PARIS, May 4 /PRNewswire/ -- Fovea Pharmaceuticals announced today positive results from its clinical proof-of-concept trial to assess the therapeutic effect of Prednisporin(TM) (FOV1101) in patients with persistent allergic conjunctivitis. Prednisporin(TM) had the same efficacy and a better safety profile (no increase in intra-ocular pressure) than PredForte(TM), a prescription drug with a 10 fold higher dose of prednisolone acetate, in patients treated for the signs and symptoms (itching...


Word of the Day
definiens
  • The word or words serving to define another word or expression, as in a dictionary entry.
The word 'definiens' comes from the Latin word 'definire', 'to define'.
Related